

May, 10, 2012

MPH Mittelständische Pharma Holding AG:

1st Quarter 2012: +15.7% Sales Growth; EBIT Margin 7.6%

In the first quarter of 2012, the MPH Group achieved a turnover of 40.66 million Euro (previous year: 35.14 million Euro) hence achieving an increase of 15.7% in comparison to the same period of the previous year. The earnings obtained before interest and tax (EBIT) were 3.09 million Euro and reached a margin of 7.6%. The earnings obtained before amortisation; interest and tax (EBITDA) were 3.19 million Euro and reached a margin of 7.87%.

The preliminary EBIT margin of the fiscal year 2011 was 7.3%.
In the first quarter of 2012, the MPH Group achieved a modest EBIT margin increase to 7.6%.

The MPH Group does expect a stronger sales growth in the next quarters of fiscal year 2012.

About the company MPH Mittelständische Pharma Holding AG:

The Berlin based company MPH Mittelständische Pharma Holding AG has strategically concentrated its activities on growth segments in the pharmaceutical market. With pharmaceutical products based on patent-free and patent-protected active substances, which are made available through the MPH group in the therapeutic areas oncology, HIV, rheumatology, neurology and cardiovascular diseases, a contribution is made towards cost reduction in the healthcare sector.

MPH Mittelständische Pharma Holding AG is listed in the Entry Standard (Open Market) of the Frankfurt stock exchange

Key capital market data for MPH Mittelständische Pharma Holding AG:

Subscribed Capital: EUR 41.167.155

Stock exchange listed class of shares: Owner held-preferred shares

Number of circulating preference shares: 19.025.000

ISIN: DE000A0NF697

WKN: A0NF69

Stock Exchange code: 93MV

Contact:

MPH Mittelständische Pharma Holding AG
Patricia Blechinger
Hubertusallee 73
D-14193 Berlin

Tel.: +49 (0) 30 897 30 86 60
Fax: +49 (0) 30 897 30 86 70

E-Mail: ir@mph-ag.de
Web: www.mph-ag.de